Age-related macular degeneration

This phase 3 trial tests whether a daily injection of elamipretide can slow vision loss in people with dry age-related macular degeneration (AMD). About 313 adults aged 55 and older with early dry AMD will receive either the drug or a placebo for 96 weeks. The main goal is to see…

This study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 mo…

This early-stage trial tests a one-time gene therapy injection (NG101) for wet age-related macular degeneration. The therapy uses a harmless virus to deliver a gene that makes a drug inside the eye, aiming to reduce the need for repeated anti-VEGF injections. About 20 adults aged…

This early-stage trial is testing a new drug called VOY-101 for people with advanced dry age-related macular degeneration (AMD) and geographic atrophy, a condition that causes blind spots. The drug is injected into the eye and aims to slow damage to the retina and preserve vision…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…

This study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …

This study tests a stem cell therapy called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy). Researchers inject retinal pigment epithelium cells derived from human embryonic stem cells into the eye to see if they can safely replace damag…

This study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed …

This study planned to test a small telescope implant inside the eye for people with severe vision loss from advanced age-related macular degeneration (AMD). The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the trial wa…

This study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to help the eye produce its own medicine to stop leaky blood vessels, potentially replacing the need for repeated eye injecti…

This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…

This study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it remains safe over time. Researchers track side effects and vision changes. The goal is to understand long-term risks, not to test if the treatment w…

This early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged…

This early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…

This study tests a new, ultra-high-resolution eye scanner that combines two imaging techniques to see the retina in 3D. Researchers will scan 10 healthy adults and 40 people with early or intermediate age-related macular degeneration (AMD). The goal is to improve early detection …

This study tests a device called AVIGA that tracks eye movements to detect vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the device's results with standard eye exams to see if it can reliably spot disease activity. The goal is…

This study compares a new numbing gel (chloroprocaine HCl 3%) to standard eye drops plus a shot for pain relief during eye injections. About 236 adults with conditions like diabetic macular edema or age-related macular degeneration will take part. The goal is to see if the gel wo…

This study follows 110 people who previously took part in the AREDS or AREDS2 trials to see how age-related macular degeneration (AMD) and cataracts change over time. Participants get a yearly eye exam, including vision tests and eye photos, and may give a blood sample. The goal …

This study follows 400 people with intermediate age-related macular degeneration (AMD) for about 3 years. Researchers watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disease. No…

This study follows people with advanced dry age-related macular degeneration who previously received a one-time injection of the experimental treatment VOY-101. Researchers are monitoring participants over the long term to check for any side effects related to the treatment. The …

This pilot study tests whether older adults with intermediate age-related macular degeneration (AMD) can eat 2 or 4 whole eggs daily for 5 months. The main goal is to see if people can stick with the diet, not to prove eggs improve vision. Researchers will also measure changes in…

This study looks at how common Charles Bonnet Syndrome (CBS) is in people with vision loss from conditions like macular degeneration or glaucoma. CBS causes complex visual hallucinations without mental illness. Researchers will survey 640 participants to measure how often it happ…

This study is testing whether taking a tiny sample of fluid from the front of the eye is safe for people with dry age-related macular degeneration (AMD). Researchers will analyze proteins in the fluid to see if they change over time. The study includes 50 adults aged 50 to 89, so…

This study looks at a specific type of blood vessel growth under the retina, called non-exudative type 1 macular neovascularization (MNV), in people with age-related macular degeneration (AMD). Researchers want to see if these vessels actually help preserve vision rather than har…

This study follows 300 patients with chronic eye conditions like glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy who recently received treatment. Researchers will measure changes in eye pressure, vision, and other outcomes over time. The goal is to unde…

This study is looking at how genetics, diet, lifestyle, and medications work together to influence the risk of age-related macular degeneration (AMD), a leading cause of vision loss. Researchers will collect blood samples and health information from 1,800 adults in Portugal. The …